Annual report pursuant to Section 13 and 15(d)

Royalty Purchase Agreements - Agenus (Details)

v3.20.4
Royalty Purchase Agreements - Agenus (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Sep. 20, 2018
USD ($)
product
Nov. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Agreements          
Payments to acquire milestones and royalties     $ 1,200 $ 19,300  
Proceeds from issuance of long-term debt       9,500  
Long-term royalty receivables     34,575 34,375 $ 15,000
Revenue from contracts with customers     27,941 17,276  
Impairment of long-term royalty receivable     0 $ 0  
Royalty Purchase Agreement | Merck Immuno-Oncology Product | Agenus          
Agreements          
Amount of milestone achieved   $ 10,000      
Agenus          
Agreements          
Cash receipts for achievement of contractual milestones     1,000    
Agenus | Royalty Purchase Agreement          
Agreements          
Payments to acquire milestones and royalties $ 15,000        
Long-term royalty receivables 15,000        
Impairment of long-term royalty receivable     $ 0    
Agenus | Royalty Purchase Agreement | Silicon Valley Bank Loans          
Agreements          
Proceeds from issuance of long-term debt $ 7,500        
Agenus | Royalty Purchase Agreement | Incyte Immuno-Oncology Assets          
Agreements          
Royalties on net sales (as a percent) 33.00%        
Number of licensed products related to milestone and royalties | product 6        
Purchased percentage of milestones 10.00%        
Agenus | Royalty Purchase Agreement | Merck Immuno-Oncology Product          
Agreements          
Royalties on net sales (as a percent) 33.00%        
Purchased percentage of milestones 10.00%        
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones $ 59,500        
Amount of milestone achieved   1,000      
Cash receipts for achievement of contractual milestones   $ 1,000